Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NGj5eXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC1xsDPxE1? NX24UpJIPDkEoHi= M1G4WIJtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>? MofsNlY{PTB3NkW=
NP69 M3TMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f3cGlEPTB;M{GuOlnDuTJwNUSg{txO MVmyOlI2OjV5NR?=
NP460 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TqO2lEPTB;MkKuPFXDuTFwMUig{txO NXrTV|lGOjZ{NUK1O|U>
C666-1 NXPTS4JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrTTWM2OD1zOT65OeKyQC57MzFOwG0> NF\STm0zPjJ3MkW3OS=>
C666-1 NVHWe5k4S2WubDDWbYFjcWyrdImgRZN{[Xl? NIXLS5cyOCEEtV2= NF\zd5g1QCCq NVzub4dkTE2VTx?= NYjTT4NLe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu NHrmVYkzPjJ3MkW3OS=>
C666-1  NXTjW2NMTnWwY4Tpc44hSXO|YYm= NHGz[HkyOCEEtV2= M3fYWFI1KGh? NWDIeIt1TE2VTx?= M3v0V4FkfGm4YYTld{B1cGVicEWzJJBifGi5YYmsJJVxemWpdXzheIlv\yCyNUOsJJAzOSCjbnSgUYRuOg>? NWW5bY5zOjZ{NUK1O|U>
C666-1 Mn7KRZBweHSxc3nzJGF{e2G7 Mn;sNVAhyrWP MX:0PE84OiCq M4\LZmROW09? NUG0bWVGe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8h[2m|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ M361fFI3OjV{NUe1
A549 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH2N5IzPCCq MVHJR|UxRTF5Lk[4JOKyKDRwNUKg{txO M{DHfFI3OTJ3MkOw
A549-NTC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5XVczPCCq NIe2c45KSzVyPUG5MlQzKMLzIEGuPVYh|ryP MoT0NlYyOjV{M{C=
A549-920 NVT4SXJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL6NlQhcA>? NVqzVI1PUUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?= NWDM[FFuOjZzMkWyN|A>
CRL-5908 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO1NlQhcA>? NV\nUm8xUUN3ME2zPE44OSEEsTCyMlQ{KM7:TR?= NHXn[28zPjF{NUKzNC=>
L6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjMR5lDOTEEoN88UeKh MYWyOE81QC95MjDo MkLHSG1UVw>? NIPYRnNqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? MUKyOVg4OTd7NB?=
C2C12 M2rWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WwT|ExyqEQvF5CpC=> NEHnU|QzPC92OD:3NkBp MmH3SG1UVw>? MoPGbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v M4\lc|I2QDdzN{m0
MCF-7  NWHjTYRSTnWwY4Tpc44hSXO|YYm= MYKxNOKh|ryP M3zzTGROW09? MWnpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> M3roRlI2PzB{N{Cz
DU4475  NUXifZFETnWwY4Tpc44hSXO|YYm= NFSwR2Y2NzFyL{KwJO69VQ>? M3\mclI1yqCq NHnqXmdld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 M1n3R|I2PTR5MUe0
SMMC-7721 NEH0ToZHfW6ldHnvckBCe3OjeR?= MlHTNVAh|ryP MX[0PEBp MVnEUXNQ NHPYVmxk[XW|ZYOgSG5CKESVQjDkZY1i\2V? MWiyOVU1PDN4MR?=
SMMC-7721 NHfGTZJHfW6ldHnvckBCe3OjeR?= NFn3TJAyOCEQvF2= NEm2eWE1QCCq NVfMWVBJTE2VTx?= NWTmVJIzcW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? NGnhVVQzPTV2NEO2NS=>
SMMC-7721 MYnGeY5kfGmxbjDBd5NigQ>? M1vMXFExKM7:TR?= MoPxOFghcA>? NYO2eJJDTE2VTx?= MUHpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7B Ml7aNlU2PDR|NkG=
SMMC-7721 MVHGeY5kfGmxbjDBd5NigQ>? MUWxNEDPxE1? M1fnclM3KGh? NYHG[nN4TE2VTx?= M3;aXINifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 NG\BUmgzPTV2NEO2NS=>
MCF-7 M{HMU2Z2dmO2aX;uJGF{e2G7 MXOxNOKh|ryP M4rXPFAuOjRiaB?= NFXvUFNqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= NITybI4zPTR6MkO3Ny=>
OVCAR10 NVzhVJZQTnWwY4Tpc44hSXO|YYm= M173OlExyqEQvF2= NHy3SVQzOWkEoB?= MUHEUXNQ NIHxVYFqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ NY[4bVhbOjV2Mk[1OFg>
NCI-H23 NUG2TldZTnWwY4Tpc44hSXO|YYm= NGjGXI0yOMLizszN NY\zNY9vOjGqwrC= NEXFNFZFVVOR Mkm2bY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> NUjhbmhLOjV2Mk[1OFg>
A2780 Ml;BSpVv[3Srb36gRZN{[Xl? MWOxNOKh|ryP MoHZNlFpyqB? NX\vNIZjTE2VTx?= NV:xV2FvcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MVqyOVQzPjV2OB?=
NCI-H23 NHTwSYZHfW6ldHnvckBCe3OjeR?= NEX4TIkyOMLizszN MlvJNlFpyqB? NV7zW5FITE2VTx?= MkLB[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= NXvNZ24{OjV2Mk[1OFg>
A2780 MniwSpVv[3Srb36gRZN{[Xl? NVjHTnFlOTEEoN88US=> MXeyNYjDqA>? MlrESG1UVw>? MUfk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MYqyOVQzPjV2OB?=
HCT116  MljYSpVv[3Srb36gRZN{[Xl? NV;GW2M4OTBiwsXN MoHJNlQhcA>? NFT3emRk[XW|ZYOgZUBxPTNvZHXw[Y5l\W62IITleJJieGyxaXSgS|Eu[XK{ZYP0JIlvKGSrcHzvbYQhUEOWMUG2JINtd26nczDEN{BidmRiREi= NYTIXndxOjV|OECwOVU>
MCF-10CA1a MoHjSpVv[3Srb36gRZN{[Xl? NX[wWlZNOTEEoN88US=> M2\CSFQ5KGh? NYPQV2xCTE2VTx?= NFe4VZhqdmirYnn0d{Bj[XOjbDDpcpZie2mxbjDhcoQhemWmdXPl[EBVT0ZvzsKzMYlv\HWlZXSgbY53[XOrb36geI8h[mG|YXygcIV3\Wy| NW\MUm9SOjV{NUe3Nlk>
MCF-10A1  M3HYPWZ2dmO2aX;uJGF{e2G7 NYPzO4RTOTEEoN88US=> NIHvcHgzPC92ODDo Ml\iSG1UVw>? NXjhSnh[cW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi NIn2XFgzPTJ3N{eyPS=>
MCF-10CA1a M3zkcWZ2dmO2aX;uJGF{e2G7 MkXBNVDDqM7:TR?= NYjHeHNzOjRiaB?= M{WwcmROW09? MWTk[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>? NGPidFMzPTJ3N{eyPS=>
MCF-10CA1a NH;hVmFHfW6ldHnvckBCe3OjeR?= MUexNOKh|ryP MorGNlQhcA>? M3TydmROW09? NFvybFJqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NFrMcXozPTJ3N{eyPS=>
SK-BR-7 MYnGeY5kfGmxbjDBd5NigQ>? M3jvblExyqEQvF2= MWmyOEBp Ml7MSG1UVw>? Ml\NbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NFrudm0zPTJ3N{eyPS=>
SUM102PT MorQSpVv[3Srb36gRZN{[Xl? M2rwR|ExyqEQvF2= MniyNlQhcA>? NEjaZYZFVVOR NUm5W4hMcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NU\kbWt5OjV{NUe3Nlk>
RAW 264.7 M33WcWZ2dmO2aX;uJGF{e2G7 NEPrTWEyOMLizszN Mn;LN|AhdWmw NFe2eWlxemW4ZX70d{B1cGVicEWzJJJm\HWldHnvckBqdiC{ZYPwc45{\SC2bzDMVHM> M4TsR|I2OTd{NUS3
RAW 264.7 Ml3ESpVv[3Srb36gRZN{[Xl? NFnzXGIyOMLizszN NILhZVA{OCCvaX6= M2nnbJJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= MlLjNlUyPzJ3NEe=
RAW 264.7 Mn3BSpVv[3Srb36gRZN{[Xl? M3;4PFExyqEQvF2= M3rSWVMxKG2rbh?= NET4U5VqdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> Mn3TNlUyPzJ3NEe=
MCF7  M1nXemNmdGxiVnnhZoltcXS7IFHzd4F6 NGf3ZWIzNjViwsXN NFfKZpk2KGR? MlrwSG1UVw>? MWXz[Y5{cXSrenXzJG1ETjdidH:gVGFTWCCrbnjpZol1cW:w MYGyOVA5PTlyMh?=
MCF7  NH;CXVRHfW6ldHnvckBCe3OjeR?= MojsNk42KML3TR?= MorhOFghcA>? MX7EUXNQ MVjk[YNz\WG|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=> MUOyOVA5PTlyMh?=
ACHN MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWWwMlUuOTBizszN M3TScVAuPiCm NIDIUFFFVVOR MYrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2m2fVI2ODZ5N{i3
Caki-2 M1X6S2NmdGxiVnnhZoltcXS7IFHzd4F6 MoHTNE42NTFyIN88US=> NWXwSHZ7OC14IHS= NWT3d4lETE2VTx?= NVmzboFIcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoXENlUxPjd5OEe=
A498 MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX\V[nN[OC53LUGwJO69VQ>? MXWwMVYh\A>? Mli0SG1UVw>? NHr2O3BqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYqyOVA3Pzd6Nx?=
115 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1j6dFAvPS1zMDFOwG0> MnrBNE03KGR? M3W3UmROW09? NEjKVG1qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYmxcHFQOjVyNke3PFc>
117 NIrFSW9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2jFcFAvPS1zMDFOwG0> MYewMVYh\A>? NWn4bXN1TE2VTx?= MmfKbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWKyOVA3Pzd6Nx?=
ACHN MVrGeY5kfGmxbjDBd5NigQ>? NGXSb2YxNjVxMT:1JO69VQ>? M37Wc|Q5KGh? Mni1SG1UVw>? MnWycIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? MV[yOVA3Pzd6Nx?=
Caki-2 M2HNOGZ2dmO2aX;uJGF{e2G7 NEPweY4xNjVxMT:1JO69VQ>? MYW0PEBp MoXKSG1UVw>? MVLs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MXyyOVA3Pzd6Nx?=
A498 MoXLSpVv[3Srb36gRZN{[Xl? MlO5NE42NzFxNTFOwG0> M2DGXlQ5KGh? MkLvSG1UVw>? NGP2ZZZt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NYDTVYprOjVyNke3PFc>
115 NYTSNGhoTnWwY4Tpc44hSXO|YYm= M4frcFAvPS9zL{Wg{txO NHvmOW01QCCq NWD0[FQ3TE2VTx?= MYLs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NGXnSZIzPTB4N{e4Oy=>
ACHN NInIXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr0dlE2KM7:TR?= MY[0PEBp M2G2UGROW09? MlLtbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NHPsemwzPTB4N{e4Oy=>
Caki-2 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfhTY1XPSEQvF2= MlThOFghcA>? MX7EUXNQ M3;qOYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NFLldoszPTB4N{e4Oy=>
A498 NFf6cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PxZ|Uh|ryP MUK0PEBp MmDtSG1UVw>? NInTTnJqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MWGyOVA3Pzd6Nx?=
115 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTKOUDPxE1? MVS0PEBp NV7lWlVSTE2VTx?= MXTpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= M4[zN|I2ODZ5N{i3
ACHN M2raRmZ2dmO2aX;uJGF{e2G7 NGrjZoU2KM7:TR?= MXO0PEBp NGfnPGVFVVOR MofXbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= M4\HcVI2ODZ5N{i3
Caki-2 MnvoSpVv[3Srb36gRZN{[Xl? MmHNOUDPxE1? NH\pTI41QCCq NXfaVG5OTE2VTx?= Mmi4bY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= M1HyR|I2ODZ5N{i3
A498 MkPZSpVv[3Srb36gRZN{[Xl? M1vnNlUh|ryP NXXMVVk5PDhiaB?= Ml2wSG1UVw>? MlTLbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NVLvbGtUOjVyNke3PFc>
115 NGHySFFHfW6ldHnvckBCe3OjeR?= MYS1JO69VQ>? NFPPVZE1QCCq NU\BXmVlTE2VTx?= NVjMWIVUcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> M{Hlb|I2ODZ5N{i3
MOLM-13 NEPzbHhHfW6ldHnvckBCe3OjeR?= M1fwdlbDqM7:TR?= NXv5PIg2OC16IHi= NUnVWGdNTE2VTx?= MnT4bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ MnnmNlQ5QDVyOEK=
MOLM-13 MmPxSpVv[3Srb36gRZN{[Xl? NULzU4lkPsLizszN NHyx[Yg3KGh? MVTEUXNQ NFm5TXdmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi|cEmw MlvGNlQ5QDVyOEK=
HepG2 NVn3eJVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHiyfG04OiCq M3\YVmROW09? NXf1OGtOUUN3ME2zOU45PiEEsTCyMlkh|ryP M4jwVVI1QDh2OEC5
HepG2/As NY\VcYdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon5O|IhcA>? M3\5WmROW09? M1;jNWlEPTB;NkiuNVMhyrFiOT62JO69VQ>? M4e4flI1QDh2OEC5
SMMC7721 NV7HT4NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK3NkBp NXPBWWdKTE2VTx?= NXq5OnYyUUN3ME2zNU4zQCEEsTC0MlIh|ryP MYeyOFg5PDhyOR?=
SMMC7721/Ac Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHnO|IhcA>? MlnTSG1UVw>? MWLJR|UxRTV3LkKxJOKyKDVwMEOg{txO NEDN[2ozPDh6NEiwPS=>
Huh-7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ewUlczKGh? NYfFUmRMTE2VTx?= NInHNmlKSzVyPUOzMlk3KMLzIEOuPUDPxE1? MoXjNlQ5QDR6MEm=
Hep3B M{Xxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW3NkBp M1f3dmROW09? NGHDTHdKSzVyPUKwMlE5KMLzIEGuPFQh|ryP M4DINlI1QDh2OEC5
HepG2 M{\vZWFxd3C2b4Ppd{BCe3OjeR?= MYrpcoR2[2W|IHHwc5B1d3Orcx?= M3m0[FI1QDh2OEC5
SMMC7721 M1LhUGFxd3C2b4Ppd{BCe3OjeR?= MXnpcoR2[2W|IHHwc5B1d3Orcx?= MoL2NlQ5QDR6MEm=
Huh-7 MUnBdI9xfG:|aYOgRZN{[Xl? M1zLNolv\HWlZYOgZZBweHSxc3nz MoCwNlQ5QDR6MEm=
Hep3B MljWRZBweHSxc3nzJGF{e2G7 M4nVfYlv\HWlZYOgZZBweHSxc3nz NWC4XWl3OjR6OES4NFk>
U2OS  MUfGeY5kfGmxbjDBd5NigQ>? NF76NmczOCEQvF2= MnzGNlQhcA>? M{L4[olv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= NITvcGEzPDh4N{K1PS=>
AML2 NISzdIhCeG:ydH;zbZMhSXO|YYm= MYqyM|ExKM7:TR?= NWLLNHhmOjRxNEigbC=> M4KxeYlv\HWlZYOgZZBweHSxc3nz MlzYNlQ3PTl5NEm=
MOML13 NX;1NVlESXCxcITvd4l{KEG|c3H5 MUKyM|ExKM7:TR?= MVmyOE81QCCq NVWwe4ZicW6mdXPld{BieG:ydH;zbZM> NX7wTnN1OjR4NUm3OFk>
AML2 Mmq3SpVv[3Srb36gRZN{[Xl? M{\YOFEx|ryP M33Hb|IwPCCq MmfmbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= NGPWU5ozPDZ3OUe0PS=>
AML3 MVPGeY5kfGmxbjDBd5NigQ>? MnnQNVDPxE1? M4TUV|IwPCCq MoTXbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= NEG3VVUzPDZ3OUe0PS=>
MOML13 MUPGeY5kfGmxbjDBd5NigQ>? M3i4NVEx|ryP MkP0Nk81KGh? M3PDOolv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz NF3aNVgzPDZ3OUe0PS=>
BeWo NFHOc5dHfW6ldHnvckBCe3OjeR?= MlnyN|AhyrWP MnH3NlQhcA>? NXLjN5djcW6lcnXhd4V{KHB3MzygUYRuOixicEKxJIFv\CCSdX3hJIF1KHSqZTDwdo91\WmwIHzleoVt MUKyOFQ6QDF3NB?=
BeWo NYDmb|hbSXCxcITvd4l{KEG|c3H5 NXWzVGZwOzBiwsXN NXTWTIdiOjRiaB?= MnK1bY5kemWjc3XzJIFxd3C2b4Ppdy=> MXeyOFQ6QDF3NB?=
OCI MojOSpVv[3Srb36gRZN{[Xl? M{PFWVExKM7:TR?= M3\RdFI1KGh? MXn1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? MmS5NlQ1PzN3NkK=
MOLM Mn2zSpVv[3Srb36gRZN{[Xl? NVfoV2k5OTBizszN M{fGN|I1KGh? NYO5emNqfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u NYTtNHBQOjR2N{O1OlI>
U2OS  NYXB[GhtTnWwY4Tpc44hSXO|YYm= NV\KSFl3OjBizszN MnjBNlQhcA>? MUTpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv MYOyOFM3PjByNx?=
RKO NHnQeJlHfW6ldHnvckBCe3OjeR?= NIL6e2UzOCEQvF2= MoDPNlQhcA>? MXHpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv MYiyOFM3PjByNx?=
U2OS  MVnGeY5kfGmxbjDBd5NigQ>? NXK2W5l7OjBizszN M37ZRlI1KGh? NV\EUmV[cW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> MUOyOFM3PjByNx?=
RKO NUTpXnFtTnWwY4Tpc44hSXO|YYm= NEi3cJAzOCEQvF2= NYDCXFdoOjRiaB?= MVLpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= M1vuRVI1OzZ4MEC3
SMMC-7721  MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHT5bFQyNjJ3LUKwJO69VQ>? NF7IUIMzPC92OD:3NkBp NVHJ[Zc2TE2VTx?= NVXkOmtGcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MYiyOFI5PjNzMh?=
HuH-7 MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYjZdW5ZOS5{NT2yNEDPxE1? NIPQW|IzPC92OD:3NkBp NGr0WGtFVVOR M4HYWIlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MUiyOFI5PjNzMh?=
SMMC-7721  M{fhSGFxd3C2b4Ppd{BCe3OjeR?= NV7jWFJzOjBizszN M2r0bVQ5KGh? NYrSW2kyTE2VTx?= Mn6ybY5lfWOnczDhdI9xfG:|aYO= M33sUlI1Ojh4M{Gy
HuH-7 NHPFRXRCeG:ydH;zbZMhSXO|YYm= M4TPUVIxKM7:TR?= M{TXdFQ5KGh? MX;EUXNQ NInDWGdqdmS3Y3XzJIFxd3C2b4Ppdy=> NX3kOFlkOjR{OE[zNVI>
SMMC-7721  NWT4UmRDTnWwY4Tpc44hSXO|YYm= NYTyS3NbOTBizszN NHGwXmI{PiCq NFLRU29FVVOR M325TIRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ MX6yOFI5PjNzMh?=
HuH-7 MXjGeY5kfGmxbjDBd5NigQ>? MkH6NVAh|ryP NW\JZWR3OzZiaB?= NGPjO4VFVVOR M3PuToRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ M2HtXlI1Ojh4M{Gy
AT2 NHLROo1HfW6ldHnvckBCe3OjeR?= MlPyOU8yOCEQvF2= NF3sRpRt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= M3;JXVI1OjRyMkCz
REH M{jtZmZ2dmO2aX;uJGF{e2G7 NVLNbI5vPS9zMDFOwG0> M{[5RYxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li MnjONlQzPDB{MEO=
UoCB6 M2PDZmZ2dmO2aX;uJGF{e2G7 NXzR[opLPS9zMDFOwG0> M37Fboxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NXLCW5ZPOjR{NECyNFM>
AT2 NX62NZNlS2WubDDWbYFjcWyrdImgRZN{[Xl? NXrCfYtlOC1{NTFOwG0> NWHTd4s1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NV6zVY05OjR{NECyNFM>
REH NEnaNFdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGfUfI0xNTJ3IN88US=> NFTkd2dqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M1vtV|I1OjRyMkCz
UoCB6 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mo\tNE0zPSEQvF2= M4HlOIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NI\BRpgzPDJ2MEKwNy=>
A2780 MWfGeY5kfGmxbjDBd5NigQ>? NYXsPJB1PS9zMD:yNEDPxE1? MYeyOEBp M1[1[JVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NWfL[oprOjRzM{[xOFc>
H460 NYP5VHgzTnWwY4Tpc44hSXO|YYm= M3Hhd|UwOTBxMkCg{txO M{jiclI1KGh? MYr1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? NX:yVnBZOjRzM{[xOFc>
Lovo  M1\VUWZ2dmO2aX;uJGF{e2G7 M4nWXVUwOTBxMkCg{txO M3HGelI1KGh? MYT1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? NUPCfYFvOjRzM{[xOFc>
A2780 NVLNfJpFSXCxcITvd4l{KEG|c3H5 M3[4fVUwOTBxMkCg{txO NYC4VYhrOjRiaB?= M3Xne4VvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MX[yOFE{PjF2Nx?=
H460 MWPBdI9xfG:|aYOgRZN{[Xl? M2POTFUwOTBxMkCg{txO MWiyOEBp MV3lcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> NHr6eJczPDF|NkG0Oy=>
Lovo  MoTDRZBweHSxc3nzJGF{e2G7 NETDc|k2NzFyL{KwJO69VQ>? NWS1[Xg2OjRiaB?= M4TUXIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN M1XCUlI1OTN4MUS3

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID